Asia Pharma R&D Leaders Summit 2017
March. 21 ( Tuesday ) to March 22 ( Wednesday ), 2017
A 24hour dynamic and livable city in Chengdu High-Tech Zone offers opportunities to leverage the China – Singapore Biomedical Ecosystems.
The Singapore-Sichuan Hi-Tech Innovation Park (SSCIP) is the first iconic integrated urban development project jointly developed by Singapore and Sichuan (China). It is located in the South Park of Chengdu Hi-Tech Industrial Development Zone (CDHT), the core area of state-level Tianfu New Area, and serves as the bridge connecting Chengdu city center with Tianfu New Area.
SSCIP is a modern new town that serves innovation-driven enterprises and creative talents in a vibrant city that integrates innovation, ecology and culture elements. Tapping on the strong industry development, masterplanning & management experiences in Singapore and the rich resources & strong industry capabilities in Chengdu, SSCIP serves as a platform for international companies to enjoy the best of both world and participate in the growth of China’s vast western & central regions. Covering an area of 10.34 km2, the project broke ground on 8 May 2012 and is expected to be completed by 2020. Designed for a residential population of 120,000 and a working population of between 120,000 to 150,000, SSCIP consists of 6 complementary clusters surrounding a 600,000m2 green core - the “Xinchuan Heartbeat Central Park”. The Central Park provides amenities and spaces for community activities and aims to transform SSCIP into “A City in A Garden”. The expressways and major trunk roads within SSCIP have been constructed and are in use. Global investment promotion has begun and significant commitments from companies to set up R&D and HQ operations within SSCIP have been secured.
As an ideal city for work, live, play and learn, SSCIP will be a prominent high-end integrated township development in West China, home to innovation-driven enterprises and top talents.
Established in Germany in 1912, M+W Group has a strong and celebrated history of more than 100 years of excellent client service. We thrive on being an engineering-led project delivery construction company; and we exist to unlock the potential of our clients by delivering high-tech, complex engineering projects. Our clients achieve their goals with our technical solutions, and are fully assured that their projects and assets are in reputable hands. Represented in over 30 countries, M+W Group maintains staffing levels of 6,000 dedicated employees. As a privately owned company, we seek to deeply understand the needs and drivers of our clients, and we choose to form trusted partner relationships. We act predictably, whilst constantly communicating and managing expectations, so that we can meet our commitments. We always add value in terms of quality, cost, technical excellence and innovation.
Microconstants China provides PK/bioanalytical laboratory services and integrated early stage clinical trial management services to pharmaceutical and biotech companies worldwide with global compliance in mind.
Our in-house OECD GLP-compliant bioanalytical laboratory specializes in method development, method validation, and sample analysis of small molecules, proteins, and peptides using LC/MS/MS, HPLC/UV, and ELISA for preclinical and clinical PK samples according to applicable regulations and guidelines of China CFDA, USEFDA, EMA, MHLW, and other regulatory agencies.
To improve GCP compliance, Microconstants China implements ICH GCP quality system in our partnering clinical trial centers, which are CFDA GCP certified and specialize in conducting FIM, PK and BE studies, as well as late phase clinical trials for product registration in China and abroad. Microconstants China’s staff is actively involved in quality assurance and clinical trial management at our clinical sites.
Sichuan Kangcheng Biotechnology is a contract research organization (CRO) located in the prosperous and time-honored city of Chengdu in Southwestern China. Founded and affiliated with Sichuan University West China Hospital, Kangcheng continues to develop innovative animal disease models ranging from rodents to non-human primates. We are particularly strong on minimally-invasive catheterization for cardio-cerebral vascular diseases, patient-derived xenograft models, in situ xenograft models, molecular imaging, neurological studies augmented with automated behavioral assessment and dynamic CSF sampling from cisterna magna. With a highly professional team, state-of-the-art equipment, and AAALAC-accredited animal facilities, we provide standard or customized preclinical screening or efficacy evaluation services to our domestic and international customers. We have helped many clients to win IND approval in both China and USA. Our top priority is to dedicate all our efforts to your business success!
Founded in 2004, Sundia MediTech Company Ltd. is a leading China-based CRO providing a broad range of high-quality, cost effective drug discovery and development services. Capitalizing on its broad service offerings, experienced scientists and advanced research facilities and equipment, Sundia helps its customers discover and develop novel drug candidates efficiently. Sundia currently provides services to over 160 customers globally, including a vast majority of the top 20 pharmaceutical and biotechnology companies in the world, as well as fast-growing biotechnology and specialty pharmaceutical companies and renowned academic and research institutions. Sundia currently boasts an experienced and strong R&D tem, comprised of over 700 employees, of over 70% have post-graduate degrees and an average of 15 years of relevant industry experience. The Company conducts its laboratory and development activities in three primary facilities in China: a) Shanghai Zhangjiang Hi-Tech Park; b) Shijiazhuang; and c) Taicang.
CrownBio is a Cutting Edge Translational Technology Company Making Precision Medicine a Reality
CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing challenges in oncology, cardiovascular, and metabolic disease Drug Discovery.
Our premier Translational Platforms for cancer and metabolic disease help our clients accelerate their new drug development programs. CrownBio develops world-leading preclinical efficacy models and provides both in vitro and in vivo testing services and preclinical research products. We are a global company with facilities across the world in the United States, United Kingdom, China, and Taiwan.
We Help our Clients Accelerate Drug Discovery, Gain Insight and De-Risk Ushering Candidates into the Clinic
As a comprehensive solution provider, CrownBio helps reveal the best clinical possibilities with our proprietary HuPrime®, HuKemia®, HuBase™, HuMark™, HuTrial™, and HuSignature™ platforms enabling the rapid translation of a lead compound into a successful clinical candidate.
CrownBio's cutting-edge, proprietary, Translational Technology Platforms provide robust and scientifically sound end-to-end solutions for preclinical drug development.
The Premier Translational Platforms for Advanced Drug Discovery From large-scale in vitro and in vivo efficacy studies of drug candidates, to running surrogate trials in tandem with human clinical trials, CrownBio's well-characterized Translational Platforms deliver comprehensive and catered solutions for biopharmaceutical companies. By providing the data needed to inform and accelerate oncology and cardiovascular and metabolic disease (CVMD) therapeutic development, CrownBio helps our clients make smarter decisions about their drug candidates.
With more experience than anyone in the industry, CrownBio's global resources help customers answer the most challenging questions about human biology.
CrownBio's portfolio of cutting edge technologies includes the world's largest commercial collection of validated Patient-Derived Xenograft (PDX) models. At CrownBio we are seeking to recapitulate the diversity and complexity of human cancer biology in the laboratory.
Our Translational Technology Platforms are helping our clients make precision medicine a reality.
Lee’s Pharmaceutical Holdings Limited (“Lee’s”) is a research-based Hong Kong biopharmaceutical company with more than 20 years of operation in China’s pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, clinical, regulatory, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 15 products in the market place. Lee’s focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee’s development program is lauded with over 40 product candidates stemming from both internal R&D efforts and collaborations with US, European and Japanese companies; including promising compounds to treat liver cancer and pulmonary hypertension.
In 2010, Lee’s has been honored an outstanding achievement in ranking “No. 2 of (China) Best Small-Cap” in the Asia’s Best Companies Poll conducted by the leading regional financial magazine FinanceAsia showing the extensive recognition in the investment community of its seasoned management and effective corporate governance. Since 2011, Lee’s was awarded as one of the “Best Under a Billion” companies by Forbes Asia. The election of the final 200 with entrepreneurial characteristics is based on earning growth, sales growth and shareholders’ return on equity in the past 12 months and over three years. The mission of Lee’s is to become a successful specialty biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharmaceutical is available at .
CVie Therapeutics Limited (CVie) is a subsidiary of Lee’s and a biopharmaceutical company that focuses on discovering, developing and commercializing novel targeted therapies for the treatment of cardiovascular/renal diseases with unmet medical need in the Greater China region, Europe, US and other international markets. Our development programs focus on the treatment of specific subsets of patients with cardiovascular/renal disorders through personalized medicines that target specific disease causative mechanisms and achieve better efficacy and safety profiles. · CVie is led by a management team with global experience and expertise in the discovery, development and commercialization of therapies for cardiovascular/renal diseases. Currently, CVie has two assets in ongoing Phase IIb clinical trials: Rostafuroxin for the pharmacogenomics treatment of Primary Hypertension and Istaroxime for the intravenous treatment of Acute Heart Failure. A phase II trial on renal proteinuria (diabetes) with Rostafuroxin is planned. Finally, Istaroxime analogs are under preclinical investigation for the oral treatment of Chronic Heart failure (CHF). CVie is looking for partnership in the development of our assets in western countries.
Beijing East IP Ltd. was founded by Dr. GAO Lulin, the founding Commissioner of the State Intellectual Property Office (SIPO), and a group of experienced Chinese and international attorneys to provide top quality intellectual property services in China. Beijing East IP Ltd. is a registered patent prosecution firm before the State Intellectual Property Office (SIPO). Together with Beijing East IP Law Firm, a registered law firm before the Justice Department of the People’s Republic of China founded and presided by Dr. GAO, we offer a complete set of intellectual property services ranging from patent and trademark prosecution, litigation to other intellectual property rights protections and enforcements. We also represent and provide consultations to multinational and Fortune 500 corporations in handling intellectual property issues and litigations arising out of their China portfolios. Our professionals are enthusiasts who devote their career in intellectual property and technology law to provide leading intellectual property services in China. Most of them obtained M.S. and Ph.D. in engineering or science from leading universities in China, Japan, U.S. and Europe. Our attorney’s enthusiasm and qualifications allowed them to acquire both extensive legal experiences and diverse technical expertise through handling many landmark intellectual property cases in China. Our managing team and attorneys possess some of the most valuable resources in China to provide clients top quality intellectual property services.
Shanghai Beshining Law Office was founded in 2013 by main partner Xue Qi and his team from Shanghai Zhixin Patent Agent Ltd., and its headquarters is located in Shanghai.
As one of the few leading law offices authorized to engage in patent and trademark, we currently house more than one hundred personnel including lawyers, patent attorneys, and other legal and technical professionals with diverse background and expertise.
Our partners and their team have been providing nearly thousands of domestic and foreign enterprises with full intellectual property legal service and comprehensive domestic and foreign legal service of patent, trademark, copyright, integrated circuit layout design, anti-unfair competition and trade secret. The quantities of patent applications, trademark applications and lawsuits are all top rated nationwide. Especially, our team in Chemistry, Pharmaceuticals and Biology in which we have 16 lawyers and 38 patent attorneys is in the top tier of China., and our firm enjoys a patent grant rate of over 90% for invention in such areas. For two consecutive years (2015-2016), our team was awarded the title of Outstanding IP Service Team in China by China IP Magazine and China Daily IPR Channel.
HD Biosciences Co., Ltd. is a biology-focused preclinical drug discovery contract research organization (CRO) with operation facilities in Shanghai, China and La Jolla, California. The company offers comprehensive service platforms around target validation, plate-based pharmacology, hit identification and lead discovery, therapeutic antibody discovery, in vivo pharmacology, as well as other research and development services. The company currently collaborates with eight of the world’s ten largest pharmaceutical companies and has established strategic partnership in many key R&D areas with the impacts to portfolio development. The strong scientific expertise, high quality and consistent deliveries, which constantly meet or exceed client’s expectations, have earned the company a great reputation in the industry and helped the company to build its widely recognized leadership in preclinical contract research services.
ScinoPharm is a leading process R&D and active pharmaceutical ingredients (API) manufacturing service provider to the global pharmaceutical industry. With its FDA approved cGMP production facilities in Taiwan and China, ScinoPharm offers services ranging from custom synthesis of early phase clinical materials to commercial production. ScinoPharm serves over 300 customers worldwide, including most brand and all top-ten generic pharmaceutical companies.
Specialized in high potency APIs, ScinoPharm has developed a broad product portfolio in the oncology category and has filed DMFs in as many countries as possible, at >743 DMF registrations worldwide, with 52 in the US.
ScinoPharm has built extensive technical expertise in the fields of small molecules and peptides over the last 19 years. The company’s strict adherence to intellectual property protection and compliance with environmental, health and safety codes makes it a preferred API supplier for major pharmaceutical companies as well as new drug development companies in contract research and manufacturing services. Already the leader in providing oncology APIs to regulated markets worldwide, ScinoPharm has been expanding into the field of oncological injectable formulations, which will provide a vertically integrated, one-stop-shop service for our existing API customers. For more information, please visit the company’s web site at
Help Stem Cell Innovation is a leading stem cell biotechnology company in China. We deploy Nobel prize-graded technique and combine with our intellectual patents to provide iPS cells reprogrammed from human monocytes and differentiated cardiomyocytes, hepatocytes and other cell types and tissues with high quality, purity and reproducibility.
Help Stem Cell Innovation has unique advantage in collaboration with domestic and international hospitals and universities, thus we provide not only healthy donor-derived iPSC-somatic cells, but also numerous types of Disease Specific iPSC-somatic cells for both academic and industrial customers, offering iPSCs for disease modeling and promise iPSC-derived somatic cell platform for Drug Screening. Products and services are based on series of NovoCellTM somatic cells differentiated from iPSCs, include, but not limited to, NovoCellTM-Cardiomyocytes, NovoCellTM-Hepatocytes, NovoCellTM-Hepatic Spheroids and NovoCellTM-Neural Progenitor Cells. Our mission is dedicating our efforts to translational research in regenerative medicine, providing better products and services for national stem cell research, drug development, precision medication and biobanking.
BioVillage, a biotech park under newly constructing, is located in Ningbo’s Hangzhou Bay New Zone, southern bank of Hangzhou Bay Bridge,where it is the center of 4 main large cities geographically: Shanghai, Ningbo, Hangzhou and Suzhou. Hangzhou Bay New Zone is one of the National-level Economic Development Zones. Being called as the Dazzling Pearl of Eastern China, the world has witnessed its rapid growing, and it is appealing more and more brightest talents. It covers 16.7 hectares in total, in which 250,000㎡of buildings with various functions will be constructed including incubator, office buildings, state-of-the-art GMP pilot laboratory, cutting-edge test & analysis platform and SPF experimental animal platform…, etc. The goal is to create a science park with garden style, in an internationalized way.
A good solution for any fund needs is schemed out: a professional VC specializing in investments in early-stage companies only in the park will be established very soon.
Asia Pharma R&D Leaders Summit 2017  |  Telephone: +86 21 6172 6970  |  E-mail:
© 2016 Asia Pharma R&D Leaders Summit 2017- All rights reserved